(855) 778-6444

Medical Study Shows Brain Chemistry Influences Empathy

brain chemistry, empathy, medical study

Could a pill be developed that boosts empathy by altering brain chemistry? According to a new research study this could be possible at some point in the future. The research suggests that the sensitivity to inequality that we have is influenced by the neurochemical balance in our brain, and changing the neurochemistry could induce more empathy in people. The medical study was performed at the University of California, Berkeley and the University of California, San Francisco. When a drug which causes prefrontal cortex neurochemical changes was given the level of empathy and fairness felt was increased. This was seen by the increased willingness to engage in and exhibit prosocial behaviors. Additional research is still needed, but the hope is that new diagnostic tools and treatments can be developed to treat individuals with conditions that cause low empathy for others.

The medical study on empathy and brain chemistry is important, because many mental disorders can impact empathy and this may be due to neurochemical changes that occur when the mental disorder starts to develop. University of California, Berkeley’s Haas School of Business assistant professor and co-principal investigator Ming Hsu said “Our study shows how studying basic scientific questions about human nature can, in fact, provide important insights into diagnosis and treatment of social dysfunctions.” Andrew Kayser, University of California, San Francisco assistant professor of neurology and a co-principal study investigator, explained “Our hope is that medications targeting social function may someday be used to treat these disabling conditions.”

New Medical Study Uses Ketamine Nasal Spray to Treat Major Depressive Disorder

ketamine nasal spray, treatment resistant major depressive disorder, medical study

A new medical study is using Ketamine nasal spray as a treatment for major depressive disorder which has been resistant to other forms of treatment. The research study was conducted by New York’s Icahn School of Medicine at Mount Sinai and the study results have been published in the Biological Psychiatry online journal. The Ketamine nasal spray study involved 20 participants, and these participants received either ketamine nasal spray or saline nasal spray for 2 days. The study used double blind crossover methods to ensure the integrity and accuracy of the results. After receiving the drug or saline placebo study participants were asked to complete the Montgomery-Asberg Depression Rating Scale so that any changes in the severity of the depression could be noted.

The goal of the ketamine nasal spray medical study was to determine whether this drug could be used to treat individuals who have treatment resistant major depressive disorder. The results of the study were very promising. Out of 20 participants only 18 completed the two days of treatment. Of these 18 people only 1 in the saline group showed an improvement in depression severity. 8 individuals in the ketamine nasal spray group showed an improvement in the severity of their depression. According to James W. Murrough, M.D. “One of the primary effects of ketamine in the brain is to block the NMDA [N-methyl-d-aspartate] glutamate receptor. There is an urgent clinical need for new treatments for depression with novel mechanisms of action. With further research and development, this could lay the groundwork for using NMDA targeted treatments for major depressive disorder.”